Photo
Business Update

Reuters business newsletter, your daily business coverage.

Subscribe

Amylin bullish on diabetes, obesity drugs

Tue Nov 7, 2006 1:18pm EST

Reporter's Notebook

[-] Text [+]

By Julie Steenhuysen and Ransdell Pierson

NEW YORK (Reuters) - Amylin Pharmaceuticals Inc.'s (AMLN.O: Quote, Profile, Research, Stock Buzz) chief operating officer said on Tuesday that Wall Street is underestimating the potential of the company's experimental obesity drugs and predicted strong near-term growth for its diabetes medicines, even as competition looms.

Daniel Bradbury, who is slated to become chief executive by next summer, offered the bullish outlook at the Reuters Health Summit.

Bradbury stressed the promise of a longer-acting form of the company's flagship diabetes drug, Byetta, which is known by the chemical name exenatide.

The new product, known as exenatide LAR, would only be injected once a week rather than twice daily for Byetta. Like Byetta, it would be sold in partnership with Indianapolis drugmaker Eli Lilly and Co. (LLY.N: Quote, Profile, Research, Stock Buzz). Analysts expect it to reach the market by 2010.

Bradbury stressed that Byetta had weight-loss benefits that could help it withstand competition from a new class of oral diabetes drugs coming on the market, notably Merck & Co. Inc.'s (MRK.N: Quote, Profile, Research, Stock Buzz) recently approved drug Januvia, and Novartis AG's (NOVN.VX: Quote, Profile, Research, Stock Buzz) similar experimental drug, Galvus.

Many analysts have fretted that Byetta sales, $126 million in the third quarter, could suffer because of Januvia, which also can be used to avoid or delay the need for insulin injections.

Asked if Januvia posed a major competitive threat to Byetta sales and its extended-release version, Bradbury replied: "I really do not see it like that."

He said the midterm future of the company could hinge on LAR. "Many people have estimated that the LAR will be a multibillion dollar product," he said, declining to give his own forecast.  Continued...

 
Global Environment Oct 06 - 8, 2008 Energy
Autos II Sep 30 - Oct 01, 2008 Hotels/Casinos
Restructuring Sep 22 - 26, 2008 Financial Services/Exchanges
Autos Sep 15 - 17, 2008 Autos
Russia Investment Sep 08 - 9, 2008 Country Summits

What are Summits?

Reuters Summits are your direct link to top business leaders, investors and regulators. Our journalists interview heavyweights in a particular industry, spin out hard-hitting breaking news and sharp analysis that can often move markets. If you want to understand what the insiders are thinking, look for Reuters Summits.  Launch Full Video 

 

Stay connected. Get e-mailed alerts with schedules, speaker lists, and headlines from upcoming and live Industry Summits.